Systemic lupus erythematosus anti-dsDNA antibodies

Swaak, T., and Smeenk, R., Detection of anti-dsDNA as a diagnostic tool A prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). 

We do not currently have data pertaining to the predictive ability of antinuclear antibodies with respect to development of lupus. However, a study using serum samples from 130 active-duty personnel in the United States military who developed systemic lupus erythematosus documented the presence of antinuclear antibodies, anti-Ro antibodies, anti-La antibodies, antiphospholipid antibodies, and anti-dsDNA antibodies a mean of 1-3 years before the occurrence of symptoms (Arbuckle et al., 2003). 

Anti-TNF-a drugs have recently been approved for the treatment of a number of autoimmune diseases, including rheumatoid arthritis and Crohn disease. A number of adverse consequences, including the development of antinuclear antibodies and anti-dsDNA antibodies and the autoimmune diseases leukocytoclastic vasculitis and systemic lupus erythematosus, have been reported following treatment with anti-TNF-a drugs (Hyrich et al., 2004). 

Systemic lupus erythematosus (SLE). A chronic, remitting-relapsing inflammatory autoimmune disease affecting multiple organ systems, such as the skin, joints, serosal membranes, kidneys, blood cells, and central nervous system. The disease is very heterogeneous in clinical expression and serological factors. Autoantibodies directed against nuclear components ( - antinuclear antibodies) are typically detected. Anti-dsDNA, anti-Sm, and antiphospholipid antibodies are used as classification criteria. 

Several studies have reported that retinoids are effective for animal models of autoimmune diseases. Lupus nephritis is a major cause of mortality among systemic lupus erythematosus patients. ATRA inhibits IFN-y cytokine production from Thl and production and deposition to the kidneys of anti-DNA antibody IgG2a, and suppresses proteinuria and renal involvement in NZB/WFl mice, which are used as a lupus nephritis model (Nozaki et al. 2005). In an open clinical trial, seven patients with active lupus nephritis were treated with ATRA. As a result, four patients showed improvements in clinical symptoms and laboratory findings, including proteinuria and anti-dsDNA antibody levels. There were no adverse effects of ATRA therapy in any patient (Kinoshita et al. 2009). 

---